<HashMap><database>biostudies-literature</database><scores/><additional><submitter>de Jong R</submitter><funding>Coalition for Epidemic Preparedness Innovations</funding><pagination>145</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12227699</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(1)</volume><pubmed_abstract>One of the concerns regarding vaccine safety during the COVID-19 pandemic was the potential manifestation of vaccine-associated enhancement of disease (VAED) upon SARS-CoV-2 infection. To investigate the suitability of the Syrian hamster model to test for VAED, we immunized animals with an experimental formaldehyde-inactivated, alum-adjuvanted SARS-CoV-2 vaccine preparation. In two independent experiments, challenge infection did not result in an enhancement of the clinical disease in vaccinated animals compared with mock-vaccinated animals. However, at early timepoints (2-5 days) post-challenge, lung histopathology progressed faster and was more prominent in vaccinated hamsters and lung tissue showed elevated mRNA levels of IL-4 and IL-13. At later time points, cytokine responses and lung</pubmed_abstract><journal>NPJ vaccines</journal><pubmed_title>Hamsters immunized with formalin-inactivated SARS-CoV-2 develop accelerated lung histopathological lesions and Th2-biased response following infection.</pubmed_title><pmcid>PMC12227699</pmcid><funding_grant_id>NA</funding_grant_id><pubmed_authors>de Jong R</pubmed_authors><pubmed_authors>Salguero FJ</pubmed_authors><pubmed_authors>Hall Y</pubmed_authors><pubmed_authors>Oreshkova N</pubmed_authors><pubmed_authors>Wiese KE</pubmed_authors><pubmed_authors>Vreman S</pubmed_authors><pubmed_authors>Carroll M</pubmed_authors><pubmed_authors>Bewley KR</pubmed_authors><pubmed_authors>de Swart RL</pubmed_authors><pubmed_authors>Gonzales JL</pubmed_authors><pubmed_authors>Gerhards NM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Hamsters immunized with formalin-inactivated SARS-CoV-2 develop accelerated lung histopathological lesions and Th2-biased response following infection.</name><description>One of the concerns regarding vaccine safety during the COVID-19 pandemic was the potential manifestation of vaccine-associated enhancement of disease (VAED) upon SARS-CoV-2 infection. To investigate the suitability of the Syrian hamster model to test for VAED, we immunized animals with an experimental formaldehyde-inactivated, alum-adjuvanted SARS-CoV-2 vaccine preparation. In two independent experiments, challenge infection did not result in an enhancement of the clinical disease in vaccinated animals compared with mock-vaccinated animals. However, at early timepoints (2-5 days) post-challenge, lung histopathology progressed faster and was more prominent in vaccinated hamsters and lung tissue showed elevated mRNA levels of IL-4 and IL-13. At later time points, cytokine responses and lung</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jul</publication><modification>2026-07-15T06:44:57.954Z</modification><creation>2025-07-28T03:04:00.413Z</creation></dates><accession>S-EPMC12227699</accession><cross_references><pubmed>40615384</pubmed><doi>10.1038/s41541-025-01160-7</doi></cross_references></HashMap>